Last reviewed 2026-04-20 · How we verify

SACCHARIN

Saccharin, a marketed sweetener, binds to sweet receptors on the tongue to mimic sweetness, positioning it as a widely recognized non-caloric sugar substitute. Its key strength lies in its long-standing market presence and the upcoming 2028 patent expiry for its key composition, which may offer extended exclusivity. The primary risk is the potential for increased competition post-patent expiry, which could impact market share and revenue.

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Erythema
• Itching
• Swelling
• Tenderness
• Pain
• Generalized skin erythema
• Urticaria
• Pruritus
• Angioedema
• Rhinitis
• Wheezing
• Laryngeal edema

Serious adverse events

• Fatal systemic adverse reactions

Key clinical trials

• Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes (NA)
• SweetSpot - The Effect of Non-nutritive Sweeteners on Health (NA)
• Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects (NA)
• Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis (PHASE2)
• Short-Term Effects of Sucralose and Saccharin on Blood Sugar and Gut Microbiota in Type 2 Diabetes (NA)
• Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants (PHASE1)
• Carbohydrate Mouth Rinse (Small-Sided Soccer Games) (NA)
• The Impact of Sage Extract on GTS B and D Gene Expression in S. Mutans (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• SACCHARIN CI brief — competitive landscape report
• SACCHARIN updates RSS · CI watch RSS